peptides protocol FAQ

Intestinal barrier repair is a structural process, not a symptomatic one. Most patients don't 'feel' tight junction restoration the way they feel reduced bloating from dietary changes. The biomarker to track is zonulin. A protein that regulates tight junction permeability. Elevated serum zonulin correlates with increased intestinal permeability. Testing zonulin at baseline and again at 4–6 weeks provides objective evidence of barrier improvement even when symptoms lag behind structural repair. If zonulin remains elevated after 6 weeks, the issue may not be structural protein deficit. It could be ongoing antigenic exposure or autoimmune gut inflammation requiring immune-modulating peptides.

Discard it immediately. Cloudiness indicates protein aggregation or bacterial contamination, both of which render the peptide ineffective and potentially harmful. TB-500 should remain clear and colorless throughout its viable window. Clouding within 7 days suggests either improper reconstitution technique (injecting air into the vial, shaking instead of swirling) or storage temperature excursion above 8°C. Reconstitute smaller batches using fresh bacteriostatic water, and verify your refrigerator maintains 2–8°C consistently. Even brief warming during door-open periods can destabilize peptides.

Compounded peptides are not inherently inferior, but quality variance is substantial. Unlike FDA-approved drugs, compounded peptides do not undergo batch-level potency verification or purity testing. A 2023 analysis published in Peptides journal found that 18% of tested compounded peptide vials contained less than 80% of the stated peptide content, and 7% contained no detectable active compound. If you're not seeing expected results from a compounded source, the issue may be potency, not dosing. Real Peptides synthesizes every compound through small-batch production with exact amino-acid sequencing and third-party purity verification.

Reduce injection volume and increase frequency rather than switching injection sites away from the injury. BPC-157 works through local receptor activation. Distant subcutaneous administration (e.g., abdomen when treating a shoulder injury) eliminates the proximity advantage. Irritation typically stems from injection volume exceeding 0.5mL in a single site or bacteriostatic water concentration above 0.9% benzyl alcohol. Split the daily dose into two 0.25mL injections 12 hours apart, or reconstitute at lower peptide concentration to increase total volume without exceeding the alcohol threshold.

Yes, if structural barrier repair is the goal. Probiotics modulate gut microbiota composition and reduce inflammatory byproducts like lipopolysaccharides. L-glutamine provides fuel for enterocyte metabolism. Neither directly stimulates collagen synthesis or tight junction protein expression the way BPC-157 or KPV does. Research from the American Journal of Physiology found that L-glutamine supplementation improved intestinal permeability markers in critically ill patients, but the effect plateaued at 4–6 weeks. Combining approaches is not redundant. It's layered intervention addressing different mechanisms.

Mild redness lasting 10–15 minutes post-injection is normal. It reflects localized histamine release and increased blood flow. Persistent redness, heat, or swelling beyond two hours suggests either an allergic reaction to the peptide or bacterial contamination during reconstitution. Stop injections immediately and consult your prescribing physician. If you develop fever, spreading erythema, or purulent drainage, seek medical evaluation for possible abscess formation. Sterile technique failures are the primary cause of injection site infections. Every reconstitution requires alcohol swabs, clean surfaces, and single-use syringes.

No. Never inject into or immediately adjacent to an open wound. The risk of introducing bacteria into unhealed tissue far outweighs any localized peptide benefit. Administer BPC-157 and TB-500 systemically (lower abdomen, outer thigh) until the incision is sealed and dry. Once epithelialization is complete (typically days 7–10 for clean surgical closures), you can transition to wound-adjacent injection if desired. Topical GHK-Cu is safe on closed incisions and delivers localized effect without needle insertion.

Begin with TB-500 immediately. You're already in the proliferative phase where fibroblast activity is peaking. Dose 2.5mg twice weekly through day 21. Add GHK-Cu if wound closure is incomplete or scar quality is a concern. You've missed the inflammatory window for BPC-157's anti-cytokine effect, but TB-500's impact on tissue scaffolding and angiogenesis remains fully relevant. Research from the University of Illinois showed that TB-500 initiated on day seven still produced 28% faster wound closure compared to controls. Delayed start reduces the benefit but doesn't eliminate it.

Discard it immediately. Do not attempt to use it. Cloudiness indicates either bacterial contamination introduced during reconstitution or protein aggregation caused by incorrect pH, temperature shock, or expired BAC water. Visible particles are often rubber stopper fragments cored by a dull or oversized needle, or precipitated peptide aggregates. Neither condition is reversible. Using contaminated or aggregated peptide solutions introduces infection risk and guarantees zero bioavailability. The denatured protein won't bind to target receptors.

Temperature excursion above 8°C for more than 4 hours causes measurable potency loss in most research peptides. If the vial was at room temperature (20–25°C) for 8–12 hours, expect 15–30% reduction in bioavailability depending on the peptide's thermal stability profile. For heat-sensitive compounds like Cerebrolysin or P21, overnight ambient storage may reduce potency by 40–60%. Document the temperature excursion and adjust dosing upward if continuing the study, or discard and reconstitute a fresh vial if precision is critical.

Bacteriostatic water's 0.9% benzyl alcohol preservative maintains antimicrobial efficacy for 28 days post-opening. Beyond that window, bacterial contamination risk rises exponentially even under refrigeration. Some peptides retain structural stability past 28 days, but without antimicrobial protection the solution is unsafe for injection. If your study extends beyond four weeks, reconstitute smaller batches more frequently rather than mixing the entire supply upfront. For long-duration research protocols involving compounds like Survodutide or Mazdutide, plan reconstitution timing around the 28-day sterility ceiling.